A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns

Simply Wall St.

03/02

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616800404"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616800404\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616800404?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-03-02 14:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616800404","market":"us","top_or_hot":-1,"title":"A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns","media":"Simply Wall St.","content":"<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-03-02 14:21</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation","article_id":"2616800404","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616800404","pubTimestamp":1772432465,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b with net income of US$1.41b.\nSee our latest analysis for Teva Pharmaceutical Industries.\nAt a share price of US$33.86, Teva’s short term share price returns over 7 and 30 days have been relatively muted. However, the 90 day share price return of 25.97% and very strong 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4007":"制药","BK4566":"资本集团","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4557":"大麻股","NYSE":"纽交所","TEVA":"梯瓦制药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4596":"哈里斯概念","BK4559":"巴菲特持仓"},"translate_title":"一年强劲的股东回报后看看梯瓦制药工业公司（纽约证券交易所股票代码：TEVA）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"NYSE":1.5},"content_text":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b with net income of US$1.41b. See our latest analysis for Teva Pharmaceutical Industries. At a share price of US$33.86, Teva’s short term share price returns over 7 and 30 days have been relatively muted. However, the 90 day share price return of 25.97% and very strong 1 year total shareholder return of 111.62% point to momentum that has built meaningfully over the past year. If Teva’s rebound has you rethinking where growth could come from next, it may be worth scanning 27 healthcare AI stocks as another way to spot health related opportunities tied to data and automation. With Teva reporting US$17.26b in revenue, US$1.41b in net income and trading at US$33.86, plus an indicated 42.63% intrinsic discount, is the market offering a genuine entry point or already pricing in future growth? AdvertisementMost Popular Narrative: 10.8% Undervalued Teva Pharmaceutical Industries’ most followed valuation story currently anchors fair value at US$37.95 per share versus the last close at US$33.86, framing the stock as trading below that narrative fair value while hinging heavily on future execution in R&D and affordable medicines.  Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme. Here is how bullish and cautious views are shaping up around valuation, execution, and growth.  Read the complete narrative. Curious what sits behind that fair value gap and the 2026 focus point? The narrative leans on a specific revenue glide path, firmer profit margins, and a future earnings multiple that assumes investors reward consistent execution rather than just short bursts of progress. Result: Fair Value of $37.95 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could change quickly if reliance on a few branded drugs, pressure on affordable medicines pricing, or a heavy US$15b plus debt load start to bite. Find out about the key risks to this Teva Pharmaceutical Industries narrative. Another Angle On Valuation The fair value narrative presents Teva as 10.8% undervalued at US$33.86, but the price tag tells a different story. On a 28x P/E, the shares trade above the US Pharmaceuticals industry at 20x, peers at 21.2x, and the 24.3x fair ratio indicated by our model. This gap suggests investors are already paying a premium for execution and growth that involve risk. If the market moves closer to the fair ratio, how comfortable are you with the valuation cushion at today’s price? See what the numbers say about this price — find out in our valuation breakdown. NYSE:TEVA P/E Ratio as at Mar 2026Next Steps If this mix of optimism and concern around Teva feels familiar, do not wait on others to frame the story for you. Check the 3 key rewards and 2 important warning signs and weigh those trade offs yourself. Looking for more investment ideas? Teva might be on your radar now, but you do not want your portfolio relying on a single story when there are other opportunities worth your attention.  Spot potential value opportunities early by scanning our list of 47 high quality undervalued stocks that pair solid fundamentals with discounted share prices. Prioritise resilience by reviewing 76 resilient stocks with low risk scores, where companies show lower risk scores that may suit a steadier approach to compounding wealth. Hunt for under the radar opportunities through our screener containing 24 high quality undiscovered gems, highlighting quality names that many investors might be overlooking right now.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}